Sentences with phrase «ibrutinib in»

FDA Approved Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 therapy.

Not exact matches

Patients in the trial had been on ibrutinib for a minimum of six months and had not achieved a complete response when they received an infusion of engineered cells split over three consecutive days.

In March 2016, Penn researchers published a study in Blood that showed long - term ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in micIn March 2016, Penn researchers published a study in Blood that showed long - term ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in micin Blood that showed long - term ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in micin CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in micin mice.

The team will present on the first 10 patients in the trial, each of whom had been taking ibrutinib for at least six months but had not achieved a complete remission.

Jennifer A. Woyach, M.D., of Ohio State University, Columbus, and coauthors described the characteristics of patients who discontinued ibrutinib therapy and their outcomes in a group of 308 patients participating in four trials at a single institution.

The results suggest that ibrutinib restored T cell activity in the patients.

«Reasons for ibrutinib therapy discontinuation in patients with chronic lymphocytic leukemia.»

Longer follow - up will reveal the durability of these results, the authors said, and may support the evaluation of a first - line approach with ibrutinib and CAR therapy in an effort to remove the need for chronic therapy.

An analysis based on disease subtype showed that ibrutinib produced complete or partial responses in 37 percent (14 of 38) of patients with ABC DLBCL but only 5 percent (1 of 20) of patients with GCB DLBCL.

For example, a drug called ibrutinib has been tested in clinical trials to treat an aggressive form of non-Hodgkin lymphoma, diffuse large B - cell lymphoma (DLBCL).

The targeted agent ibrutinib has shown a high response rate in both treatment - naive and previously treated, relapsed, refractory chronic lymphocytic leukemia (CLL) patients older than 65.

Venetoclax has durable clinical activity in patients with relapsed / refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.